Search research articles
Contact Us
Filters
Showing results (401-410 of 868) with videos related to
Page
of 87
Sort By:
British Journal of Haematology
|
September 4, 2009
Impact of prior therapies on the relative efficacy of bortezomib compared with dexamethasone in patients with relapsed/refractory multiple myeloma
Dan T Vogl, Edward A Stadtmauer, Paul G Richardson, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 20, 2007
Novel therapy with 2-methoxyestradiol for the treatment of relapsed and plateau phase multiple myeloma
S Vincent Rajkumar, Paul G Richardson, Martha Q Lacy, et al.
Journal of Controlled Release : Official Journal of the Controlled Release Society
|
October 15, 2014
Liposomal carfilzomib nanoparticles effectively target multiple myeloma cells and demonstrate enhanced efficacy in vivo
Jonathan D Ashley, Jared F Stefanick, Valerie A Schroeder, et al.
Clinical Lymphoma, Myeloma & Leukemia
|
February 21, 2026
Safety and Tolerability of CAR T-Cell Therapy in Patients With End-Stage Kidney Disease on Hemodialysis: A Case Series
Zohaib Ahmed, Walid Hamouche, Syed O Ahmad, et al.
Blood
|
November 21, 2024
Development of hyperdiploidy starts at an early age and takes a decade to complete
Mehmet K Samur, Anil Aktas Samur, Parth Shah, et al.
Advanced Healthcare Materials
|
September 24, 2021
A 3D-Bioprinted Multiple Myeloma Model
Di Wu, Zongyi Wang, Jun Li, et al.
Leukemia
|
February 16, 2020
A novel BCMA PBD-ADC with ATM/ATR/WEE1 inhibitors or bortezomib induce synergistic lethality in multiple myeloma
Lijie Xing, Liang Lin, Tengteng Yu, et al.
British Journal of Haematology
|
November 7, 2008
Bortezomib is associated with better health-related quality of life than high-dose dexamethasone in patients with relapsed multiple myeloma: results from the APEX study
Stephanie J Lee, Paul G Richardson, Pieter Sonneveld, et al.
Leukemia & Lymphoma
|
August 20, 2011
A phase 1 study of IPI-504 (retaspimycin hydrochloride) in patients with relapsed or relapsed and refractory multiple myeloma
David Siegel, Sundar Jagannath, David H Vesole, et al.
Blood Cancer Discovery
|
February 4, 2026
Rethinking Multiple Myeloma Treatment: The Biological and Clinical Insights Guiding Immune-Based Combinations
Annamaria Gullà, Madhav V Dhodapkar, Hermann Einsele, et al.
Page
of 87
Search research articles
Search
Showing results (401-410 of 868) with videos related to
Sort By:
Page
of 87
British Journal of Haematology
|
September 4, 2009
Impact of prior therapies on the relative efficacy of bortezomib compared with dexamethasone in patients with relapsed/refractory multiple myeloma
Dan T Vogl, Edward A Stadtmauer, Paul G Richardson, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 20, 2007
Novel therapy with 2-methoxyestradiol for the treatment of relapsed and plateau phase multiple myeloma
S Vincent Rajkumar, Paul G Richardson, Martha Q Lacy, et al.
Journal of Controlled Release : Official Journal of the Controlled Release Society
|
October 15, 2014
Liposomal carfilzomib nanoparticles effectively target multiple myeloma cells and demonstrate enhanced efficacy in vivo
Jonathan D Ashley, Jared F Stefanick, Valerie A Schroeder, et al.
Clinical Lymphoma, Myeloma & Leukemia
|
February 21, 2026
Safety and Tolerability of CAR T-Cell Therapy in Patients With End-Stage Kidney Disease on Hemodialysis: A Case Series
Zohaib Ahmed, Walid Hamouche, Syed O Ahmad, et al.
Blood
|
November 21, 2024
Development of hyperdiploidy starts at an early age and takes a decade to complete
Mehmet K Samur, Anil Aktas Samur, Parth Shah, et al.
Advanced Healthcare Materials
|
September 24, 2021
A 3D-Bioprinted Multiple Myeloma Model
Di Wu, Zongyi Wang, Jun Li, et al.
Leukemia
|
February 16, 2020
A novel BCMA PBD-ADC with ATM/ATR/WEE1 inhibitors or bortezomib induce synergistic lethality in multiple myeloma
Lijie Xing, Liang Lin, Tengteng Yu, et al.
British Journal of Haematology
|
November 7, 2008
Bortezomib is associated with better health-related quality of life than high-dose dexamethasone in patients with relapsed multiple myeloma: results from the APEX study
Stephanie J Lee, Paul G Richardson, Pieter Sonneveld, et al.
Leukemia & Lymphoma
|
August 20, 2011
A phase 1 study of IPI-504 (retaspimycin hydrochloride) in patients with relapsed or relapsed and refractory multiple myeloma
David Siegel, Sundar Jagannath, David H Vesole, et al.
Blood Cancer Discovery
|
February 4, 2026
Rethinking Multiple Myeloma Treatment: The Biological and Clinical Insights Guiding Immune-Based Combinations
Annamaria Gullà, Madhav V Dhodapkar, Hermann Einsele, et al.
Page
of 87